FindTrial
Sign In

Combined treatment with topical minoxidil and nano-microneedle-assisted fibroblast growth factor in male androgenetic alopecia

Combined treatment with topical minoxidil and nano-microneedle-assisted fibroblast growth factor in male androgenetic alopecia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021107
Enrollment
Unknown
Registered
2019-01-28
Start date
2018-02-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

male androgenic alopecia

Interventions

1:nano-microneedle combined with saline
2:topical 5% minoxidil
3:nano-microneedle combined with fibroblast growth factor
4:combined treatment with topical minoxidil and nano-microneedle-assisted fibroblast growth factor

Sponsors

First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 50 Years

Inclusion criteria

Inclusion criteria: Forty male patients aged 22-50 years were enrolled in this study. They were diagnosed with type II—VI AGA based on the pattern of hair loss according to the modified Norwood-Hamilton scale.

Exclusion criteria

Exclusion criteria: Patients with hypertension, coronary heart disease, diabetes mellitus, craniocerebral disease; previous systemic or topical treatment that could affect the hair cycle within the past 6 months, hair transplantation on the target areas, presence of hair disorders other than AGA and presence of any known systemic diseases.

Design outcomes

Primary

MeasureTime frame
hair density;hair diameter;hair follicle density;—

Countries

China

Contacts

Public ContactXue-Gang Xu

First Hospital of China Medical University

xuxuegang2749290@163.com+86 15840574769

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026